Anterior AI: Prior Authorization Automation for Payers

Few things in American healthcare are as universally disliked as prior authorization. A doctor recommends a treatment, and before the patient can receive it, someone at the health plan has to review the request against the plan's medical policies and decide whether to approve it. Done slowly, it delays care, sometimes dangerously. Done at scale, it consumes armies of nurses and clinicians on both sides. The work is high-volume, high-stakes, document-heavy, and deeply rules-bound, which is exactly the shape of problem AI is now good at.

A New York company called Anterior has built clinician-led AI to take it on. Its platform reads a prior-authorization request, checks it against the plan's clinical criteria, and helps the payer approve appropriate care in seconds instead of days. This is a deep look at what Anterior does, the results it reports, and, just as important, what it actually takes to deploy this inside a health plan so it delivers the return on investment it promises. That last part is where healthcare AI succeeds or fails.

Prior authorization is a bottleneck by design and a burden by accident. Health plans use it to control cost and ensure appropriate care, but the manual review process behind it is enormous. Nurses and medical directors spend their days reading clinical documentation, cross-referencing medical policies and evidence-based guidelines, and making determinations, one case at a time. For a large payer processing millions of authorizations a year, that is a vast, expensive, and slow operation, and every day of delay is a patient waiting for care.

Anterior was built to fix it from a clinical point of view rather than a purely technical one. Founded in 2022 by CEO Abdel Mahmoud, a physician, and Zahid Mahmood, the company is explicitly clinician-led, which matters in a domain where trust and accuracy are everything. The thesis is that AI can do the heavy lifting of clinical review, reading the documentation and applying the criteria, while keeping clinicians in control of the decisions that require human judgment.

Anterior is not a chatbot. It is a clinical reasoning system that operates on real authorization requests and produces review-grade output. The company structures its offering, per the Anterior platform, into two layers:

- Actions: modular AI tasks that can be applied across a health plan's workflows, the building blocks of automation.

- Solutions: pre-configured AI transformations built to demonstrate ROI, with a specific focus on prior authorization.

In prior-auth review, the platform reads the clinical documentation, evaluates it against the plan's medical policies and guidelines, and surfaces a recommendation with the supporting evidence attached and cited. A crucial design and regulatory point runs through it: the AI is built to accelerate and approve appropriate care, while determinations that deny care remain with qualified clinicians. That human-in-the-loop boundary is not a limitation bolted on afterward. In a field drawing increasing regulatory scrutiny from CMS and state consumer-protection laws, it is what makes the automation defensible.

The beneficiaries line up on every side, which is rare. Patients get faster approvals. Physicians spend less time chasing authorizations. And the health plan reclaims enormous clinical capacity while improving consistency.

The reported results are striking. Anterior says its platform reduces manual clinical review time by roughly 75 percent while maintaining 99.24 percent clinical accuracy, a figure verified by KLAS Research. A case study documented by AWS describes cancer-care approval times falling from days or weeks to as little as 155 seconds, and the company reports a 76 percent increase in auto-approvals and a 92 clinician satisfaction score in its deployments. For a regional payer covering about one million lives, Anterior estimates roughly $30 million in annual operational savings. Its platform now supports payers covering more than 50 million lives, with customers including Geisinger Health Plan and integration work alongside health-technology platforms like HealthEdge.

In February 2026 Anterior closed a $40 million round, bringing its total funding to $64 million. The oversubscribed raise included continued backing from NEA and Sequoia Capital, alongside new investors FPV and Kinnevik, following a $20 million Series A in 2024. That is a serious roster of investors betting that AI-driven prior authorization is ready to move from pilots to production across the payer market.

What makes the trajectory notable is the size of the team behind it. Anterior is doing this with a lean organization, which is a testament to the leverage the product creates, and also a clue about where the constraint lies as it scales.

Anterior is a strong example of the pattern defining enterprise AI's winners. They are not general-purpose assistants. They are vertical systems that go deep into one high-stakes, rules-bound workflow, earn trust by showing their evidence, and keep humans in control of the decisions that matter. Prior authorization is a near-perfect target: high volume, expensive clinical labor, document-heavy, and full of explicit criteria the AI can reason against.

It also spotlights the real bottleneck in enterprise AI, which is not the model. Anterior's own homepage frames its mission as helping health plans move beyond proof-of-concept into measurable ROI, and that phrase is the whole story of enterprise AI right now. Getting a capable system to a working pilot is one thing. Turning it into production capacity across a real, regulated organization is another entirely. This is the same shift reshaping how work gets delivered everywhere: the move away from renting hours and toward outcome-based delivery that is measured and proven, the model behind a modern Virtual Delivery Center.

A demo that approves a cancer-care request in 155 seconds is genuinely impressive. Turning that into millions of authorizations handled reliably across a health plan's real book of business is a deployment project, and it has several distinct pieces, none of which the software does for you.

1. Clinical criteria and policy configuration. An AI reviewer is only trustworthy if it reflects the plan's own medical policies and the evidence-based guidelines it uses. Encoding those policies, mapping them to the plan's lines of business, and validating the AI's determinations against what the plan's own clinicians would decide is careful, expert work. It is what separates output a medical director will sign from output they have to re-review.

2. Integration into payer and utilization-management systems. Value depends on the AI reaching into the systems the plan actually runs on: the utilization-management platform, the claims system, provider portals, and the clinical data sources behind them. Connecting those reliably and securely, in a HIPAA-governed environment, is substantial integration work and a common place timelines slip.

3. Compliance, fairness, and audit controls. Prior authorization is under a regulatory microscope. Deployment has to enforce the boundary that only qualified clinicians deny care, preserve complete audit trails, meet CMS interoperability and prior-authorization requirements, and stand up fairness monitoring so the system can be shown to treat members equitably. Getting these controls right is what makes the speed safe and the program survive an audit.

4. Clinician change management and trust. This is the piece that decides success. Nurses and medical directors are being asked to rely on AI for work tied to patient safety and their professional judgment. If they do not trust it, they will re-review everything and the capacity gain evaporates. Building trust takes explainability they can inspect, a rollout sequenced to the clearest wins, workflows redesigned around review rather than manual determination, and a feedback loop so clinician corrections improve the system.

5. Measurement and continuous tuning. The ROI case has to be proven in the plan's own numbers. Baseline turnaround time, auto-approval rate, accuracy, clinician satisfaction, and cost before go-live, then measure the same after, on a defined line of business, and keep tuning the criteria. Without that loop, you cannot prove the savings to the executives who funded the program or justify scaling it plan-wide.

None of those five require a better model. The bottleneck is capacity and know-how, not capability. Deploying clinical AI well is a cross-functional effort spanning the plan's medical, IT, compliance, and operations functions, and most plans do not have a spare team that understands both utilization-management workflows and AI deployment sitting idle to run it. A lean, fast-growing vendor keeps its own people focused on the product and the largest accounts. The plan's clinicians are busy reviewing cases. So the program stalls as a promising pilot, and the payer-wide ROI never fully arrives.

This is not an Anterior problem or a healthcare problem. It is the defining problem of enterprise AI, and it is why the old ways of adding capacity fall short. Hiring a permanent deployment team for a one-time rollout is slow and expensive, and staffing agencies rent bodies by the month rather than delivering a working outcome.

Plans that win with clinical AI treat deployment as the real project and resource it properly. That usually means a delivery layer that sits behind the vendor's product and the plan's team and owns the last mile: configuring the medical policies, integrating the utilization-management and claims systems, standing up the compliance and audit controls, running the clinician change management, and building the measurement loop that proves ROI.

This is exactly what a Virtual Delivery Center is built to do, and it works across regulated industries, healthcare included. AiDOOS runs elastic delivery pods that plug in alongside a product like Anterior and the plan's own people, take on the configuration and adoption work, and turn a promising pilot into production capacity. The vendor keeps its focus on the product. The plan reaches measured ROI without hiring a permanent function for a one-time push, and it pays for delivered outcomes, not effort. For how that managed-delivery model works in practice, our VDC FAQ walks through the mechanics.

The sensible way to start is small and provable: pick one line of business or one service area, get the AI fully deployed and trusted on it, measure the before and after, and use that proof to scale across the plan.

Anterior has taken one of healthcare's most painful, expensive workflows and rebuilt it around clinician-led AI that shows its evidence and keeps humans in charge of the decisions that matter. The accuracy figures, the customer base, and the backing from Sequoia and NEA say the approach is real. The technology is ready.

The question every health plan should ask is not whether the AI is accurate. It is whether the plan will actually deploy it, configure it to its policies, satisfy its regulators, earn its clinicians' trust, and prove the ROI, or whether it will stall as a pilot everyone admired. Answer that well, and the capacity and the savings are real, and patients get care faster. Leave it to chance, and even a category leader like Anterior becomes another proof-of-concept that never reached production. The model is no longer the hard part. Deployment is, and that is a solvable problem.